Caicun Zhou

Overview

Best Publications

• Osimertinib in Untreated EGFR-Mutated Advanced Non–Small-Cell Lung Cancer

  Jean-Charles Soria;Yuichiro Ohe;Johan Vansteenkiste;Thanyanan Reungwetwattana

  4403
  Citations

• Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study

  Caicun Zhou;Yi Long Wu;Gongyan Chen;Jifeng Feng

  3591
  Citations

• Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial

  Tony S.K. Mok;Yi Long Wu;Iveta Kudaba;Dariusz M. Kowalski

  3207
  Citations

• Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC

  Suresh S Ramalingam;Johan Vansteenkiste;David Planchard;Byoung Chul Cho

  2126
  Citations

• Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial

  Luis Paz-Ares;Mikhail Dvorkin;Yuanbin Chen;Niels Reinmuth

  1754
  Citations

• Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial

  Yi-Long Wu;Caicun Zhou;Cheng-Ping Hu;Jifeng Feng

  1700
  Citations

• Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials

  James Chih Hsin Yang;Yi Long Wu;Martin Schuler;Martin Sebastian

  1331
  Citations

• Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial

  Vincent A. Miller;Vincent A. Miller;Vera Hirsh;Jacques Cadranel;Yuh Min Chen

  1310
  Citations

• Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6.

  James C.H. Yang;Lecia V. Sequist;Sarayut Lucien Geater;Chun Ming Tsai

  1057
  Citations

• Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB-IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial.

  Enriqueta Felip;Nasser Altorki;Caicun Zhou;Tibor Csőszi

  1011
  Citations

• First-line erlotinib versus gemcitabine/cisplatin in patients with advanced EGFR mutation-positive non-small-cell lung cancer: analyses from the phase III, randomized, open-label, ENSURE study

  Y.-L. Wu;C. Zhou;C.-K. Liam;G. Wu

  824
  Citations

• Clinical Experience With Crizotinib in Patients With Advanced ALK-Rearranged Non–Small-Cell Lung Cancer and Brain Metastases

  Daniel B. Costa;Alice T. Shaw;Sai-Hong I. Ou;Benjamin J. Solomon

  670
  Citations

• CNS Response to Osimertinib Versus Standard Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients With Untreated EGFR-Mutated Advanced Non–Small-Cell Lung Cancer

  Thanyanan Reungwetwattana;Kazuhiko Nakagawa;Byoung Chul Cho;Manuel Cobo

  663
  Citations

• Detection and Dynamic Changes of EGFR Mutations from Circulating Tumor DNA as a Predictor of Survival Outcomes in NSCLC Patients Treated with First-line Intercalated Erlotinib and Chemotherapy

  Tony S.K. Mok;Yi-Long Wu;Jin Soo Lee;Chong-Jen Yu

  572
  Citations

• Final overall survival results from a randomised, Phase III study of erlotinib versus chemotherapy as first-line treatment of EGFR mutation-positive advanced non-small-cell lung cancer (OPTIMAL, CTONG-0802)

  Caicun Zhou;Y. L. Wu;G. Chen;J. Feng

  553
  Citations

• Icotinib versus gefitinib in previously treated advanced non-small-cell lung cancer (ICOGEN): a randomised, double-blind phase 3 non-inferiority trial

  Yuankai Shi;Li Zhang;Xiaoqing Liu;Caicun Zhou

  527
  Citations

• Single-cell profiling of tumor heterogeneity and the microenvironment in advanced non-small cell lung cancer

  Fengying Wu;Jue Fan;Yayi He;Anwen Xiong

  504
  Citations

• Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer (ZODIAC): a double-blind, randomised, phase 3 trial.

  Roy S Herbst;Yan Sun;Wilfried E E Eberhardt;Paul Germonpré

  499
  Citations

• Durvalumab, with or without tremelimumab, plus platinum-etoposide versus platinum-etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial.

  Jonathan W Goldman;Mikhail Dvorkin;Yuanbin Chen;Niels Reinmuth

  498
  Citations

• Role of IL-2 in cancer immunotherapy.

  Tao Jiang;Caicun Zhou;Shengxiang Ren

  490
  Citations